402 related articles for article (PubMed ID: 11118050)
21. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2).
Cheng LS; Liu AP; Yang JH; Dong YQ; Li LW; Wang J; Wang CC; Liu J
Cell Res; 2003 Feb; 13(1):35-48. PubMed ID: 12643348
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
[TBL] [Abstract][Full Text] [Related]
23. In vivo biotinylated recombinant antibodies: construction, characterization, and application of a bifunctional Fab-BCCP fusion protein produced in Escherichia coli.
Weiss E; Chatellier J; Orfanoudakis G
Protein Expr Purif; 1994 Oct; 5(5):509-17. PubMed ID: 7827508
[TBL] [Abstract][Full Text] [Related]
24. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application.
Goel A; Colcher D; Baranowska-Kortylewicz J; Augustine S; Booth BJ; Pavlinkova G; Batra SK
Cancer Res; 2000 Dec; 60(24):6964-71. PubMed ID: 11156397
[TBL] [Abstract][Full Text] [Related]
25. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts.
Zhang M; Zhang Z; Garmestani K; Schultz J; Axworthy DB; Goldman CK; Brechbiel MW; Carrasquillo JA; Waldmann TA
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1891-5. PubMed ID: 12569172
[TBL] [Abstract][Full Text] [Related]
26. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
27. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
28. Generation of a single-chain Fv fragment for the monitoring of deoxycholic acid residues anchored on endogenous proteins.
Kobayashi N; Ohtoyo M; Wada E; Kato Y; Mano N; Goto J
Steroids; 2005 Apr; 70(4):285-94. PubMed ID: 15784283
[TBL] [Abstract][Full Text] [Related]
29. Improved tumor targeting by combined use of two antitenascin antibodies.
Petronzelli F; Pelliccia A; Anastasi AM; D'Alessio V; Albertoni C; Rosi A; Leoni B; De Angelis C; Paganelli G; Palombo G; Dani M; Carminati P; De Santis R
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7137s-7145s. PubMed ID: 16203813
[TBL] [Abstract][Full Text] [Related]
30. [Cloning and expression of single chain Fv gene against human colorectal carcinoma].
Fang J; Song JD
Ai Zheng; 2002 Jul; 21(7):740-4. PubMed ID: 12479098
[TBL] [Abstract][Full Text] [Related]
31. Construction and characterization of a quadruplex DNA selective single-chain autoantibody from a viable motheaten mouse hybridoma with homology to telomeric DNA binding proteins.
Brown JC; Brown BA; Li Y; Hardin CC
Biochemistry; 1998 Nov; 37(46):16338-48. PubMed ID: 9819226
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
[TBL] [Abstract][Full Text] [Related]
33. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.
Hayden-Ledbetter MS; Cerveny CG; Espling E; Brady WA; Grosmaire LS; Tan P; Bader R; Slater S; Nilsson CA; Barone DS; Simon A; Bradley C; Thompson PA; Wahl AF; Ledbetter JA
Clin Cancer Res; 2009 Apr; 15(8):2739-46. PubMed ID: 19351771
[TBL] [Abstract][Full Text] [Related]
34. Design of a bifunctional fusion protein for ovarian cancer drug delivery: single-chain anti-CA125 core-streptavidin fusion protein.
Wang WW; Das D; McQuarrie SA; Suresh MR
Eur J Pharm Biopharm; 2007 Mar; 65(3):398-405. PubMed ID: 17257818
[TBL] [Abstract][Full Text] [Related]
35. Generation and application of a fluorescein-specific single chain antibody.
Schenk JA; Sellrie F; Böttger V; Menning A; Stöcklein WF; Micheel B
Biochimie; 2007 Nov; 89(11):1304-11. PubMed ID: 17686564
[TBL] [Abstract][Full Text] [Related]
36. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.
Siemers NO; Kerr DE; Yarnold S; Stebbins MR; Vrudhula VM; Hellström I; Hellström KE; Senter PD
Bioconjug Chem; 1997; 8(4):510-9. PubMed ID: 9258449
[TBL] [Abstract][Full Text] [Related]
37. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
38. Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.
Hamblett KJ; Press OW; Meyer DL; Hamlin DK; Axworthy D; Wilbur DS; Stayton PS
Bioconjug Chem; 2005; 16(1):131-8. PubMed ID: 15656584
[TBL] [Abstract][Full Text] [Related]
39. Intrabody construction and expression. II. A synthetic catalytic Fv fragment.
Ohage EC; Wirtz P; Barnikow J; Steipe B
J Mol Biol; 1999 Sep; 291(5):1129-34. PubMed ID: 10518948
[TBL] [Abstract][Full Text] [Related]
40. [Construction and expression of single chain Fv antibody against human bladder carcinoma].
Zhang M; Yu L; Huang H
Zhonghua Wai Ke Za Zhi; 2001 Oct; 39(10):792-5. PubMed ID: 16201198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
